Abstract: The invention proposes a cell-free graft, comprising (i) a cohesive, structure-forming matrix with open porosity made from a biologically and pharmaceutically acceptable material and (ii) serum. In one particularly preferred embodiment, the matrix additionally contains a gel. By virtue of a second aspect, a method of producing such a cell-free graft is proposed, whereby the matrix and the gel, if one is provided, is placed in contact with the serum. The graft may optionally be dried with serum. Alternatively, the matrix and the gel, if one is provided, are in the dried state before being placed in contact with the serum. By virtue of a third aspect, finally, the invention proposes the use of the cell-free graft for regenerating tissue and in particular for regenerating cartilage and/or bone.

Abstract: Coatings for an implantable medical device and a method of fabricating the coatings are disclosed. The coatings comprise a fluorinated polymer and a biologically beneficial polymer, an example of which includes poly(ethylene-glycol)-block poly(butylene terephthalate)-block poly(ethylene-glycol). A biologically active agent can be additionally conjugated to the biologically beneficial polymer.

Abstract: Coated tablets of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided. The tablets minimize the perceived bitterness of the medicament. A method for analyzing instantaneous dissolution of sub-microgram quantities of core material is also disclosed.

Abstract: A pharmaceutical composition is disclosed which comprises a solid dispersion of a pharmaceutical compound in a water soluble carrier, such as polyethylene glycol (PEG), and a crystallization inhibitor, such as polyvinylpyrrolidone or hydroxypropylmethylcellulose. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treatment employing said solid dispersion.

Abstract: Compositions and methods for influencing the recovery of an animal from the effects of strenuous physical activity. The compositions generally comprise about 4% to 6% readily absorbable carbohydrate; about 10% to 30% maltodextrins; about 20% to 50% starch, for a total of about 40% to 80% carbohydrate; about 20% to about 40% protein; and optionally one or more antioxidants. The methods generally comprise administering the composition to an animal within the period from about 120 minutes before initiation of or 120 minutes after completion of the physical activity.

Abstract: There is described inter alia a device having a surface comprising a layered coating wherein the outer coating layer comprises a plurality of cationic hyperbranched polymer molecules characterized by having (i) a core moiety of molecular weight 14-1,000 Da (ii) a total molecular weight of 1,500 to 1,000,000 Da (iii) a ratio of total molecular weight to core moiety molecular weight of at least 80:1 and (iv) functional end groups, whereby one or more of said functional end groups have an anti-coagulant entity covalently attached thereto.

Abstract: The present invention is directed to the use of xanthan gum, particularly heat treated xanthan gum, as a fixative in hair cosmetic compositions. Xanthan gum is advantageous in that it may be used with other hair fixatives and provides rheology modifying and other properties including excellent stiffness, gloss, dry comb, wet comb, non-flake, anti-static, feel and high humidity curl retention.

Abstract: The present application relates to pharmaceutical compositions for reducing glucose excursions in a normal subject or a subject having an insulin-related disorder or dysglycemia. The pharmaceutical composition contains one or more active agent-containing layers, which each contain a dry blended mixture including a therapeutically effective amount of a polar ionizable insulin-sensitizing oral hypoglycemic agent or a pharmaceutically acceptable salt thereof, and an amphipathic compound in monomelic form consisting of an amphipathic ionic compound in monomelic form. Each dry blended mixture contains a sufficient amount of the amphipathic ionic compound such that upon contact with an aqueous fluid, the amphipathic ionic compound forms a reverse micelle comprising the polar ionizable insulin-sensitizing oral hypoglycemic agent.

Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.

Abstract: An ophthalmic laser treatment apparatus comprises: a laser source that emits a laser beam for treatment of an affected part of a patient's eye; an optical fiber that transmits the laser beam emitted from the laser source; and a delivery optical system that irradiates the laser beam emitted from the optical fiber to the affected part of the patient's eye, the delivery optical system including: a plurality of diffraction optical elements each being configured to shape a beam profile of the laser beam at an emission end face of the optical fiber into a beam profile having one of a uniform intensity and a lower intensity in the center than on the periphery on the affected part and also to shape the laser beam to have a different spot size on the affected part of the patient's eye; and a changing unit which selectively disposing one of the diffraction optical elements on an optical path.

Abstract: A medicament carrier composition includes a medicament and a polymer component including a polyvinylpyrrolidone having a weight average molecular weight of at least 700,000 g/mol. The medicament carrier composition has a viscosity of from 500 to 5,000 cps at 250 C, is substantially free of cellulose, and includes an auxiliary polymer. The medicament carrier composition is used to form a film that is also substantially free of cellulose. The film has a consistent thickness and size, and an increased flexibility and increased moisture resistance due to the polyvinylpyrrolidone. The medicament carrier composition is also used in a method of forming the film. The method includes the steps of providing the medicament and the polymer component. The method also includes the step of combining the polymer component and the medicament to form the medicament carrier composition. The method further includes the step of drying the medicament carrier composition to form the film.

Abstract: The present invention provides a cosmetic composition comprising, in a cosmetically acceptable organic liquid medium, at least one film-forming ethylenic linear block polymer, and another film former. The film former may be soluble or dispersible in the said organic liquid medium. The composition may include an aqueous phase, in which case the film former may be soluble or dispersible in the aqueous phase. The invention further provides for the use of the combination of such a block polymer and a film former for enhancing the staying power of the said composition on the keratin materials.

Abstract: A method of treating or preventing infection at a surgical site comprising a bony defect and an implanted metal device is disclosed. Biodegradable microspheres are placed at the site and are capable of near-linear controlled release of an antibiotic agent for a predetermined period of time. The microspheres are configured to be large enough to avoid being phagocytosed and removed from the body, and small enough in diameter to not physically inhibit bone growth at said bony defect site. The microspheres are formed of polylactic-co-glycolic acid (PLGA), with or without polyethylene glycol (PEG), and sufficient antibiotic agent to produce bactericidal levels in body tissues. The microspheres exhibit near-linear delivery of the antibiotic agent for at least 4 weeks at levels exceeding the minimum inhibitory concentration (MIC) for organisms commonly found to be the cause of infections, and facilitate bone ingrowth or regrowth at the site.

Abstract: Disclosed is a topical skin care composition and corresponding methods for its use comprising water, a cationic surfactant, an occlusive skin conditioning agent, a humectant skin conditioning agent, and a silicone containing compound. The composition is dermatologically acceptable and is capable of moisturizing skin for at least twelve hours after topical application to skin even after multiple washings of the skin.

Abstract: The invention relates to a solid formulation for the oral administration of olanzapine that comprises a core of anhydrous olanzapine Form I or a pharmaceutically acceptable salt thereof and, optionally, pharmaceutically acceptable excipients, said core being coated with a functional polymer that acts as filmogenic agent. The method for obtaining it comprises: i) providing anhydrous olanzapine Form I or a salt thereof and, optionally, pharmaceutically acceptable excipients in solid form; ii) providing a functional polymer that acts as filmogenic agent; iii) preparing a dispersion of said functional polymer in an aqueous medium,—and applying the dispersion obtained in step iii) onto the solid form of step i).

Abstract: A process for producing aqueous chlorous acid solution in which chlorous acid, which is safe for the human body, is easy to handle, and less generates chlorine dioxide, is yielded and used as a disinfectant for a pretreatment in food processing. To an aqueous sodium chlorate solution is added sulfuric acid or an aqueous solution thereof in such an amount and concentration that the pH of the aqueous solution can be kept at 2.3-3.4 to thereby react them and generate chloric acid. Subsequently, hydrogen peroxide is added to the chloric acid in an amount which is equal to or larger than the amount necessary for a reduction reaction to thereby yield chlorous acid. Any one of inorganic acids, inorganic acid salts, organic acids, and organic acid salts, or two or more thereof, or a combination or these is added to the aqueous solution containing chlorous acid yielded, whereby the chlorous and acid can be present for long and the pH of the aqueous solution is regulated to regulated to 3.2-7.0.

Abstract: An amphiphilic block copolymer is disclosed. The amphiphilic block copolymer includes one or more hydrophilic polymers, one or more hydrophobic polymer, and one or more zwitterions. The invention also provides a nanoparticle and carrier including the amphiphilic block copolymer for delivery of water insoluble drugs, growth factors, genes, or water insoluble cosmetic substances.

Abstract: The present invention relates to pharmaceutical composition containing nemorubicin hydrochloride incorporated in microspheres. The compositions are useful for chemoembolization, particularly for loco regional treatment of tumors.

Abstract: Wiping products, such as facial tissues, contain a temperature change composition that can provide a cooling sensation when contacted with the skin of a user. The temperature change composition, for instance, can contain one or more phase change agents that undergo a phase change at slightly elevated temperatures. The phase change agents, in one embodiment, can have a relatively high heat of fusion. When undergoing a phase change, the phase change agents absorb heat and thereby provide a cooling feeling to the skin of a user. In one embodiment, the phase change agent comprises a straight chain hydrocarbon. Hydrocarbons useful as phase change agents include an octadecane, a nonadecane, a heptonoate, or mixtures thereof.

Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.